At Indee Labs, our mission is to make gene-modified cell therapies accessible to the masses. Our goal is to develop a uniquely gentle and scalable hardware for gene delivery to optimally treat patients with advance and otherwise incurable disease.

Our team

Ryan Pawell (Founder, Managing Director & Chief Executive Officer) is a Y Combinator alumnus, published author and subject matter expert in the areas of fluid dynamics, advanced manufacturing, and biomicrofluidics. Ryan has been invited to present his work by the Australian National Fabrication Facility, White House Cancer Moonshot Taskforce, Air Force, National Institutes of Health, and National Cancer Institute among others.
Warren McKenzie, PhD MCom CMatP (Director & Chief Executive Officer, Indee Labs Australia) is an Endeavour Executive Fellow was most recently the National Business Development Manager for the Australian National Fabrication Facility. Warren is also a Director of Advanced Alloy Holdings and HB11 Energy. He has more than 10 years of commercial scientific experience. Prior to joining Indee Labs full time, Warren was able to spin-out an early-stage academic technology into a revenue-stage business without investment.
Katherine Lau (Bioengineer and Laboratory Supervisor) is a graduate from the University of California, Berkeley (MEng) and Rutgers University (B.S.) with over 5 years of research experience. Katherine has previously worked on several BioMEMS projects including the fabrication of microcatheters for drug delivery in the brain and in vitro studies of neuron growth in microchannels after injury.
Adrian Lievano (Bioengineer) is a graduate from the University of Pennsylvania (B.S.E & M.S.E) with over 3 years of entrepreneurial experience. Adrian previously served as a research engineer at UPENN's GRASP laboratory, where he worked on autonomous robotic systems, haptic sensors, and haptic actuation systems.
Julyana Acevedo, PhD (Scientist) is a molecular biologist with 10 years of research experience in the areas of cell-mediated tissue repair, DNA damage repair and molecular activation mechanisms related to cancer and heart disease. She completed her Ph.D. in 2015 at the University of Southern California, where she researched the initiation step of ATR checkpoint activation, a signaling pathway that senses damaged DNA and coordinates its repair to prevent mutagenic effects that may lead to malignant transformation and cancer. She is an author of four peer-reviewed publications and was the recipient of a USC Center for Excellence in Genomic Science (CEGS) Graduate Scholar Fellowship.
Justin Jarrell, PhD (Senior Scientist) is a translational immunologist with 9 years of experience directing projects in human disease, biomarker and drug target discovery, and high-throughput platform development. He recently completed his PhD in Immunology at Stanford University where he discovered and implicated anti-cytokine autoantibodies in the pathogenesis of IgG4-related disease. Prior to this, Justin worked as a research associate at Stanford developing novel antigen microarrays to investigate B and T cell responses in lupus and influenza. He is an author of 12 peer-reviewed publications, recipient of the Stanford Graduate Fellowship, and is eager to apply his technical expertise, clinical knowledge, and immunology foundation to advance Indee’s gene delivery system for CAR T cell production and manufacturing.
Giles Kirby, PhD (Research Fellow) is a translational scientist with a keen interest in cell therapies. Giles brings a decade of experience in advancing the science that underpins translational regenerative and cell therapies by identifying and tackling the bottlenecks from bench-to-bedside. He made the transition from chemistry into a biological field, positioning himself to address the key challenges relating to biomaterials and biotechnology developments. His primary area of interest is currently gene technologies. Giles maintains a cross-disciplinary skillset with side interests in plasma polymers, radiophysics and electronic interfacing (hardware & software development). He is keen to apply his knowledge and understanding in advancing the Indee gene delivery system.


Heidi Hagen (Advisor) is co-founder and Chief Strategy Officer at Vineti with more than 15 years experience in commercial cell therapy. Prior to this, she successfully delivered the first operation that manufactures and distributes live autologous cellular products within an 18 hour time window to oncology patients in both the United States and Europe

Our story